Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

784P - Perioperative multimodality treatment in high-risk node-positive penile cancer: A single institution study of patients treated in a supraregional centre

Date

17 Sep 2020

Session

E-Poster Display

Topics

Tumour Site

Penile Cancer

Presenters

Constantine Alifrangis

Citation

Annals of Oncology (2020) 31 (suppl_4): S550-S550. 10.1016/annonc/annonc274

Authors

C. Alifrangis1, A.J.X. Lee2, S. Fernando1, O. Cakir3, P. Koliou1, A. Lerner1, J. Forgenie1, C. Akers3, S. HArland1, A. Freeman4, M. Walkden5, P. HAdway3, H. Alnajjar3, A. Muneer3, A. Mitra1

Author affiliations

  • 1 Division Of Cancer, UCLH - University College London Hospitals NHS Foundation Trust, NW1 2PG - London/GB
  • 2 Medical Oncology, University College London Cancer Institute, WC1E6BT - London/GB
  • 3 Department Of Andrology, UCLH - University College London Hospitals NHS Foundation Trust, NW1 2PG - London/GB
  • 4 Dept Of Pathology, UCLH - University College London Hospitals NHS Foundation Trust, NW1 2PG - London/GB
  • 5 Radiology, UCLH - University College London Hospitals NHS Foundation Trust, NW1 2PG - London/GB

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 784P

Background

The role of perioperative treatment with adjuvant radiotherapy (RT), combination chemotherapy (CT) or both modalities in node-positive penile cancer following radical lymphadenectomy is unclear. Recent guidelines suggest a benefit of perioperative CT, but question the efficacy of adjuvant RT.

Methods

Perioperative combination CT using paclitaxel/cisplatin/ifosfamade (TIP) or Cisplatin/5FU (CF) was added to our protocol of adjuvant RT in high-risk, node-positive squamous cell carcinoma of the penis. From 2007 to 2018 a total of 111 patients were treated with radical surgery including inguinal lymphadenectomy for pN2/pN3 disease at a supraregional centre. 9 were excluded due to metastatic disease at presentation and 10 were excluded due to lack of follow up. 92 patients were included in the analysis. Primary outcome was progression free survival (PFS) 2 years after surgery. Log-rank analysis of survival curves, and multivariate analysis (MVA) using Cox proportional hazard logistic regression was undertaken.

Results

Median age was 62 years. 57% (52/92) had extranodal extension (ENE). 43% (40/92) also underwent pelvic lymphadenectomy. 48% (44/92) received post-operative RT, the most recent 19% also had perioperative chemotherapy (most had TIP). The PFS at 24 months was 26% with post-operative surveillance alone, 54% with post-operative RT alone and 74% with both perioperative CT and post-operative RT. Surveillance versus RT alone resulted in PFS 7 versus 36 months, HR 2.01 (1.2-3.8) p=0.0079. Surveillance vs CT + RT PFS 7 months versus PFS not reached HR 3.4 (1.6-7) P=0.0008. MVA confirmed that CT + RT reduced risk of progression HR 0.2 (0.05-0.92) p=0.039 (Table). Table: 784P

Perioperative intervention 2 year PFS Median PFS HR 95% CI P
Surveillance 26% 7 months - - -
Adj RT alone 54% 36 months 2.8 1.2-3.8 0.0079
CT and RT 74% not reached 3.4 1.7-7.0 0.0008
MVA- variables associated with risk of progression after surgery HR 95% CI P
surveillance 2.1 1.2-3.9 0.013
Combination RT and CT 0.2 0.1-0.9 0.039
Extracapsular Spread 2.1 1.1-3.9 0.019

Conclusions

Following inguinal lymphadenectomy in high-risk node-positive penile cancer patients PFS was significantly improved in patients who received adjuvant RT alone, but the greatest PFS was seen in those who receive both perioperative CT and adjuvant RT.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.